Comparative Pharmacology
Head-to-head clinical analysis: IV PERSANTINE versus SODIUM NITROPRUSSIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IV PERSANTINE versus SODIUM NITROPRUSSIDE.
IV PERSANTINE vs SODIUM NITROPRUSSIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits adenosine deaminase and phosphodiesterase, increasing intracellular cAMP and adenosine; causes coronary vasodilation and inhibits platelet aggregation.
Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing cGMP, leading to vasodilation of both arterial and venous vessels.
0.14 mg/kg/min intravenous infusion over 4 minutes for myocardial perfusion imaging.
Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in adults; may be prolonged in patients with hepatic impairment.
Sodium nitroprusside itself has a half-life of approximately 2 minutes (converted to cyanide in erythrocytes); the metabolite thiocyanate has a terminal half-life of 2.7-7 days (prolonged in renal impairment, requiring monitoring)
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; renal excretion of unchanged drug is minimal (<1%); biliary/fecal elimination accounts for approximately 90% of the dose.
Renal: approximately 75% as thiocyanate (metabolite) with 25% unchanged; biliary/fecal: minimal (<5%)
Category C
Category C
Vasodilator
Vasodilator